ТокÑични ефекти предизвикани од хемотерапија Ñо виÑоки дози метотрекÑат кај деца Ñо акутна лимфоблаÑтна леукемија
Клучни зборови:
acute lymphoblastic leukemia, methotrexate, toxic effectsАпстракт
Intensification of systemic chemotherapy with in- clusion of high doses methotrexate (MTX) has contributed to the improvement of event-free survival in children with acute lymphoblastic leukemia (ALL). Despite this benefit, this agent might cause serious toxicity, even life-treating events during treatment. Therefore, prediction, early detection and management of toxic effects during therapy with high doses of MTX is still a great challenge for every pediatric oncologist.
The aim of our study was to evaluate the incidence of toxic effects of chemotherapy with high doses of MTX (5 g/m2) and to compare them with toxicity during application of lower doses of MTX (2 g/m2).
Retrospective record review of 77 children with medium risk ALL was done. Patients were treated in the Department of hematology and oncology at the University children's hospital in Skopje. Forty-five of them were treated with 5 g/m2 and 32 of them were treated with 2 g/m2 (historic group). Toxicity was registered according to the protocol for acute toxicity, part of the ALL BFM 95 protocol. Toxic effects were predominant in the group treated with higher doses of MTX. The most significant toxic effects were hepatotoxicity, oral mucositis and myelosuppression. More severe grade of hepatotoxicity and oral mucositis were present in the study group. In our study toxic effects were more common in the study group due to application of higher doses of MTX. Variations in toxicity between the patients of the study group are probably due to the genetic differences in the drug absorption, their excretion and cellular transport. Current studies are dedicated on discovering genetic markers which will be able to predict the risk of appearance of MTX toxicity.
##plugins.generic.usageStats.downloads##
Референци
Poplack D. Acute lymphoblastic leukemia. Vo: Pizzo P,
Poplack D, Ed. Principles and practice of Pediatric oncology,
Lippincot, 1993: 431-483.
Schrappe M, Pieters R. Acute lymphoblastic leukemia.
Vo: Pinkerton R, Plowman P, Pieters R, Ed. Pediatric
oncology, Arnold, 2004, 230-254.
BFM study group, Treatment protocol ALL-BFM 95 for
children and adolescents with acute lymphoblastic leucaemia,
a cooperative multicentar trial of the German society
for pediatric hematology and oncology, updated English
version of the original protocol, Novembеr, 10, 1997.
Schrappe M, Reiter A, Zimmerman M, et al. Long term
results of four consecutive trials in childhood ALL performed
by ALL-BFM study group from 1981-1995. Leukemia
;14: 2205-22.
Schmiegelow K. Advances in individual prediction of
methotrexate toxicity a review. Br J Haematol 2009;
: 489-503.
Gauri K, Rupal S, Sarfraz A. Experience with high dose
methotrexate therapy in childhood acute lymphoblastic
leukemia in a tertiary care centre of a developing
country. Pediatr Blood Cancer 2012; 59:448-53.
Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs
GT. Comparison of pharmacokinetics and toxicity
after high-dose methotrexate treatments in children
with acute lymphoblastic leukemia. Anticancer drugs
; 24(2): 189-197.
Vagace HM, Marzal CC, Jimenez M et al. Methotrexat –
induced subacute neurotoxicity in a child with acute
lymphoblastic leukemia carrying genetic polymorfisms
related to folate homeostasis. Am J Hematol Oncol
; 86: 98–101.
Van Hasselt JGC, van Eijkelenburg NKA, Huitema ADR,
Schellens JHM, Schouten-van Meeteren AYN. Severe
skin toxicity in pediatric patient treated with voriconazole
and concomitant methotrexate. Antimicrobial
Agents Chemother 2013; 57(6): 2878-81.
Pietrzyk JJ, Bik-Multanowski M, Balwierz W. et al. Additional
genetic risk factor for death in children with
acute lymphoblastic leukemia: A common polymorphism
of the MTHFR Gene. Pediatr Blood Cancer
; 52:364-368.
Farrow AC, Buchanan GR, Zwiener RJ, Bowman
WP and Winick NJ. Serum aminotransferase elevation
during and following treatment of childhood acute
lymphoblastic leukemia. JCO 1997; 15 (4): 1560-66.
Evans W, Relling M, Rodman J et al. Conventional
Compared with Individualized Chemotherapy for Childhood
Acute Lymphoblastic Leukemia. N Engl J Med
; 338:499-505
De Rotte M.C.F.J, Den Boer E, Bulatovik Calasan M et
al: Personalized medicine of methotrexate therapy.
Ned Tijdschr Klin Chem Labgeneesk 2012; 37: 50-53.
Luisa Garre M, Relling M., Kalwinsky D. et al. Pharmacokinetiks
and toxicity of methotrexate in children
with Down syndrome and acute lymphocytic leukaemia.
J Pediatr. 1987; Volume 111(4): 606-12
Преземања
Објавено
Како да се цитира
Издание
Секција
Дозвола
All wrights are reserved.


